Moraxella catarrhalis: from interactions with the host immune system to vaccine development

被引:0
|
作者
Su, Yu-Ching [1 ]
Singh, Birendra [1 ]
Riesbeck, Kristian [1 ]
机构
[1] Lund Univ, Skane Univ Hosp, Dept Lab Med Malmo, SE-20502 Malmo, Sweden
基金
英国医学研究理事会;
关键词
adhesins; Immune response; Moraxella catarrhalis; respiratory tract infection; vaccine; OUTER-MEMBRANE PROTEIN; NONTYPABLE HAEMOPHILUS-INFLUENZAE; NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY EPITHELIAL-CELLS; TRANSFERRIN-BINDING PROTEIN; MUCOSAL ANTIBODY-RESPONSE; NECROSIS-FACTOR-ALPHA; STREPTOCOCCUS-PNEUMONIAE; SURFACE PROTEIN;
D O I
10.2217/FMB.12.80
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Moraxella catarrhalls is a human-restricted commensal that over the last two decades has developed Into an emerging respiratory tract pathogen. The bacterial species is equipped with various adhesins to facilitate its colonization. Successful evasion of the human immune system is a prerequisite for Moraxella infection. This strategy involves induction of an excessive proinflammatory response, intervention of granulocyte recruitment to the infection site, activation of selected pattern recognition receptors and cellular adhesion molecules to counteract the host bacteriolytic attack, as well as, finally, reprogramming of antigen presenting cells. Host immunomodulator molecules are also exploited by Moraxella to aid in resistance against complement killing and host bactericidal molecules. Thus, breaking the basis of Moraxella immune evasion mechanisms is fundamental for future invention of effective therapy in controlling Moraxella infection.
引用
收藏
页码:1073 / 1100
页数:28
相关论文
共 50 条
  • [1] Vaccine development for Moraxella catarrhalis: rationale, approaches and challenges
    Murphy, Timothy F.
    EXPERT REVIEW OF VACCINES, 2009, 8 (06) : 655 - 658
  • [2] Virulence determinants of Moraxella catarrhalis: distribution and considerations for vaccine development
    Blakeway, Luke V.
    Tan, Aimee
    Peak, Ian R. A.
    Seib, Kate L.
    MICROBIOLOGY-SGM, 2017, 163 (10): : 1371 - 1384
  • [3] MID and UspA1/A2 of the human respiratory pathogen Moraxella catarrhalis, and interactions with the human host as basis for vaccine development
    Riesbeck, Kristian
    Tan, Thuan Tong
    Forsgren, Arne
    ACTA BIOCHIMICA POLONICA, 2006, 53 (03) : 445 - 456
  • [4] Vaccine targets against Moraxella catarrhalis
    Ren, Dabin
    Pichichero, Michael E.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (01) : 19 - 33
  • [5] Progress toward the development of a vaccine to prevent Moraxella (Branhamella) catarrhalis infections
    McMichael, JC
    MICROBES AND INFECTION, 2000, 2 (05) : 561 - 568
  • [6] Vaccine development for nontypeable Haemophilus influenzae and Moraxella catarrhalis:: progress and challenges
    Murphy, Timothy F.
    EXPERT REVIEW OF VACCINES, 2005, 4 (06) : 843 - 853
  • [7] Potential impact of a Moraxella catarrhalis vaccine in COPD
    Perez, Antonia C.
    Murphy, Timothy F.
    VACCINE, 2019, 37 (37) : 5551 - 5558
  • [8] Development of a shuttle vector for Moraxella catarrhalis
    Wang, W
    Attia, AS
    Liu, LX
    Rosche, T
    Wagner, NJ
    Hansen, EJ
    PLASMID, 2006, 55 (01) : 50 - 57
  • [9] Current progress with Moraxella catarrhalis antigens as vaccine candidates
    Mawas, Fatme
    Ho, Mei Mei
    Corbel, Michael J.
    EXPERT REVIEW OF VACCINES, 2009, 8 (01) : 77 - 90
  • [10] Current progress of adhesins as vaccine candidates for Moraxella catarrhalis
    Ton, Thuan Tong
    Riesbeck, Kristian
    EXPERT REVIEW OF VACCINES, 2007, 6 (06) : 949 - 956